ARDX - Conference and earnings call announcements

WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (NASDAQ:ARDX), ("Ardelyx" or the "Company") a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following investor conferences: Citi's 2026 Biopharma Back to School ConferenceLocation: New York, NYInvestor Meetings: Wednesday, September 9 2026 Cantor Global Healthcare ConferenceLocation: New York, NYFireside Chat: Thursday, September 10 at 11:30 AM ETInvestor Meetings: Thursday, September 10 Morgan Stanley 24th Annual Global Healthcare ConferenceLocation: New York, NYFireside

WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the presentation of a data analysis evaluating the long-term impact of XPHOZAH® (tenapanor) on serum electrolytes and selected nutrition biomarkers at the National Kidney Foundation's (NKF) Spring Clinical Meetings, currently underway in New Orleans. XPHOZAH is the first and only phosphate absorption inhibitor (PAI) approved by the U.S. Food and Drug Administration to reduce serum phosphorus in adults with chronic kidney disease on dialys

WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences: Leerink Partners 2026 Global Healthcare ConferenceLocation: Miami, FLPresentation: Tuesday, March 10 at 4:20 p.m. ET1x1 Meetings: Tuesday, March 10 To access the live webcast of the Leerink presentation, please visit the Events and Presentations page within the Ardelyx website at ir.ardelyx.com. A replay of the panel presentation will be available on the Ardelyx website for 30 days follo

WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that President and CEO, Mike Raab will participate in a fireside chat at the Wedbush Rewind ASN 2025 Conference on Monday, November 10, 2025 from 11:30 a.m. to 12:00 p.m. ET. To access the public webcast of the event, please visit the Events and Presentations page within the Ardelyx website at https://ardelyx.com/. A replay of the event will be available on the Ardelyx website for 30 days following the event. About ArdelyxArdel

WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences: Citi Biopharma Back to School SummitLocation: Boston, MAFireside Chat: Wednesday, September 3 at 1:00 p.m. ET1x1 Meetings: Wednesday, September 3 Cantor Global Healthcare ConferenceLocation: New York, NYFireside Chat: Thursday, September 4 at 8:35 a.m. ET1x1 Meetings: Thursday, September 4 Morgan Stanley 23rd Annual Global Healthcare ConferenceLocation: New York

WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences: Leerink Partners 2025 Global Healthcare ConferenceLocation: Miami, FLPresentation: Tuesday, March 11 at 8:00 a.m. ET1x1 Meetings: Tuesday, March 11 To access the live webcast of the Leerink presentation, please visit the Events and Presentations page within the Ardelyx website at ir.ardelyx.com. A replay of the presentation will be available on the Ardelyx websit

WALTHAM, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will present at TD Cowen's 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:50am ET in Boston. To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event. About Ardelyx, I

WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 4:30pm PT in San Francisco. To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the panel presentation will be available on the Ardelyx website for 30 days fo

Ninety percent of survey participants reported "some" or "significant" negative impact of IBS-C on their life Survey results presented in two poster presentations WALTHAM, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that results from the IBS in America 2024 supplemental survey, in partnership with Health Union, were presented at the American College of Gastroenterology's (ACG) Annual Scientific Meeting & Postgraduate Course, currently taking place in Philadelphia. Developed as an

WALTHAM, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the publication of plain language summaries of results from two clinical trials on XPHOZAH® (tenapanor), NORMALIZE and OPTIMIZE, in Current Medical Research and Opinion. The plain language summaries were developed by the authors to help adult patients with chronic kidney disease receiving dialysis, and their family members and caregivers, better understand some of the safety and efficacy data related to XPHOZAH. XPHOZAH, the fir

WALTHAM, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 12:00 p.m. ET in New York City. To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be available on the Ardel

WALTHAM, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, will present on behalf of the company at the virtual H.C. Wainwright 2nd Annual Kidney Conference on Tuesday, July 25, 2023 at 2:00 P.M. Eastern Time. To access the live webcast of the presentation, please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the presentation will be avai

WALTHAM, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7, 2023, at 8:30 a.m. ET in New York City. To access the live webcast of Ardelyx's fireside chat please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be available on the Ardelyx webs

Three posters support the important role that XPHOZAH, a novel phosphate absorption inhibitor, could potentially play in the treatment of hyperphosphatemia XPHOZAH consistently lowered serum phosphate in patients, independent of race Patients with chronic kidney disease (CKD) on maintenance dialysis who responded to treatment for hyperphosphatemia had comparable serum phosphate reductions with XPHOZAH or sevelamer XPHOZAH was effective at reducing iFGF23 in patients with CKD on maintenance dialysis WALTHAM, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-

WALTHAM, Mass., Nov. 22, 2022 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that management will participate in a fireside discussion at the 34th Annual Piper Sandler Healthcare Conference on Thursday, December 1, 2022, at 10:00 a.m. ET in New York City.   To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx w

Majority of survey respondents call for new treatments to help manage phosphorus levels WALTHAM, Mass. and NEW YORK, Nov. 4, 2022 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX) in partnership with the National Kidney Foundation (NKF), today announced results from a survey of patients with chronic kidney disease (CKD) on dialysis conducted to better understand patients' experience managing serum phosphorus levels. The survey found that more than 80% of respondents struggle to manage their serum phosphorus levels, with more than 90% citing a need for new treatment options. "Despite

WALTHAM, Mass., Sept. 6, 2022 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences: Citi's 17th Annual BioPharma ConferenceLocation: Boston, MA 1x1 Meetings: Thursday, September 8, 2022 H.C. Wainwright 24th Annual Global Investment ConferenceLocation: New York City, NY/Virtual Presentation: Tuesday, September 13, 2022, at 11:30 a.m. ET 1x1

WALTHAM, Mass., Aug. 2, 2022 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a virtual fireside chat at the 2022 Wedbush PacGrow Healthcare Conference. The fireside chat will take place on Tuesday, August 9, 2022, at 4:40 p.m. ET.   To access the live webcast of Ardelyx's presentation please visit the Events & Pre

WALTHAM, Mass., June 3, 2022 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10, 2022, at 8:30 a.m. ET in New York City.   To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor sec

Four posters support the important role that XPHOZAH, with its novel phosphate blocking mechanism, could potentially play in the treatment of hyperphosphatemiaXPHOZAH alone or in combination with binders, increased the proportion of patients able to achieve target phosphorus levels Patients reported improved experience with phosphate management routine during OPTIMIZE study, compared to previous phosphate lowering therapies Responder analysis from PHREEDOM demonstrates 77% of patients experienced phosphate lowering with XPHOZAH, with 41% of responders achieving a > 2 mg/dL decreaseWALTHAM, Mass., April 7, 2022 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded w

FREMONT, Calif. and WALTHAM, Mass., Nov. 11, 2021 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies London Healthcare Conference, which is taking place virtually and in-person on November 16 – 19, 2021. The fireside chat will be available to all registered participants on-demand between 3:00 a.m. ET on November 18, 2021 and 12:00 p.m. ET on November 19, 2021.

FREMONT, Calif. and WALTHAM, Mass., May 25, 2021 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 3:30 p.m. ET.   To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor sectio

FREMONT, Calif., Feb. 17, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference at 3:00 p.m. ET on Wednesday, Feb. 24, 2021. To access the webcast of Ardelyx's presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the fireside chat will be available on the Ardelyx web